Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study.

Vardakas KZ, Theocharis G, Tansarli GS, Rafailidis P, Falagas ME.

Arch Virol. 2016 Sep;161(9):2511-8. doi: 10.1007/s00705-016-2941-5. Epub 2016 Jul 1.

PMID:
27368992
2.

Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.

Orzeck EA, Shi N, Blumentals WA.

Clin Ther. 2007 Oct;29(10):2246-55.

PMID:
18042482
4.

Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children.

Gums JG, Pelletier EM, Blumentals WA.

Expert Opin Pharmacother. 2008 Feb;9(2):151-61. doi: 10.1517/14656566.9.2.151 .

PMID:
18201141
5.

Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.

Peters PH, Moscona A, Schulman KL, Barr CE.

Medscape J Med. 2008 Jun 4;10(6):131.

6.

Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006-2010.

Spagnuolo PJ, Zhang M, Xu Y, Han J, Liu S, Liu J, Lichtveld M, Shi L.

Curr Med Res Opin. 2016 Aug;32(8):1399-407. doi: 10.1080/03007995.2016.1176016. Epub 2016 May 12.

PMID:
27052817
7.

Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza.

Barr CE, Schulman K, Iacuzio D, Bradley JS.

Curr Med Res Opin. 2007 Mar;23(3):523-31.

PMID:
17355734
8.

Treatment with oseltamivir in children hospitalized with community-acquired, laboratory-confirmed influenza: review of five seasons and evaluation of an electronic reminder.

Wilkes JJ, Zaoutis TE, Keren R, Desai B, Leckerman KH, Hodinka RL, Metjian TA, Coffin SE.

J Hosp Med. 2009 Mar;4(3):171-8. doi: 10.1002/jhm.431.

PMID:
19301375
9.

Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan.

Liu CH, Wang JL, Su CP, Chuang JH, Chang CH, Lai MS.

BMC Public Health. 2013 Jul 12;13:646. doi: 10.1186/1471-2458-13-646.

10.

Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.

Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M.

J Antimicrob Chemother. 2011 May;66(5):1150-5. doi: 10.1093/jac/dkr089. Epub 2011 Mar 9.

PMID:
21393197
11.

Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.

Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, Liang ZA, Liang L, Zhang SJ, Zhang B, Gu L, Lu LH, Wang DY, Wang C; National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China.

N Engl J Med. 2009 Dec 24;361(26):2507-17. doi: 10.1056/NEJMoa0906612. Epub 2009 Dec 9.

12.

Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus.

Ng S, Cowling BJ, Fang VJ, Chan KH, Ip DK, Cheng CK, Uyeki TM, Houck PM, Malik Peiris JS, Leung GM.

Clin Infect Dis. 2010 Mar 1;50(5):707-14. doi: 10.1086/650458.

13.

Oseltamivir use amongst hospitalized patients infected with influenza.

Herman M, Smieja M, Carruthers S, Loeb M.

Influenza Other Respir Viruses. 2014 Sep;8(5):547-8. doi: 10.1111/irv.12260. Epub 2014 Jul 4. No abstract available.

14.

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.

Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, Dong JP, Liang LR, Li XW, Hu K, He XS, Sun YH, An Y, Yang T, Cao ZX, Guo YM, Wen XM, Wang YG, Liu YL, Jiang LD.

Ann Intern Med. 2011 Aug 16;155(4):217-25. doi: 10.7326/0003-4819-155-4-201108160-00005. Erratum in: Ann Intern Med. 2012 Jan 3;156(1 Pt 1):71.

PMID:
21844547
15.

Prescription of antiviral drugs during the 2009 influenza pandemic: an observational study using electronic medical files of general practitioners in the Netherlands.

Hooiveld M, van de Groep T, Verheij TJ, van der Sande MA, Verheij RA, Tacken MA, van Essen GA.

BMC Pharmacol Toxicol. 2013 Oct 21;14:55. doi: 10.1186/2050-6511-14-55.

16.

Evaluation of diagnostic and therapeutic approaches for suspected influenza A(H1N1)pdm09 infection, 2009-2010.

Vijayan V, Jing J, Zangwill KM.

Emerg Infect Dis. 2012 Sep;18(9):1414-21. doi: 10.3201/eid1809.111564.

17.

Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.

Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA.

Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22.

PMID:
24268590
18.

The validity of clinical practice guidelines for empirical use of oseltamivir for influenza in Thai children.

Wongsawat J, Chittaganpitch M, Ampornareekul S, Srisophaa S, Likanonsakul S.

Paediatr Int Child Health. 2016 Nov;36(4):275-281.

PMID:
26293663
19.

Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China.

Yu H, Liao Q, Yuan Y, Zhou L, Xiang N, Huai Y, Guo X, Zheng Y, van Doorn HR, Farrar J, Gao Z, Feng Z, Wang Y, Yang W.

BMJ. 2010 Sep 28;341:c4779. doi: 10.1136/bmj.c4779.

20.

Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.

Ison MG, Szakaly P, Shapira MY, Kriván G, Nist A, Dutkowski R.

Antivir Ther. 2012;17(6):955-64. doi: 10.3851/IMP2192. Epub 2012 Jun 22.

PMID:
22728756

Supplemental Content

Support Center